Apogee Therapeutics (APGE) Equity Average (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Equity Average data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Equity Average rose 55.35% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 55.35% YoY) and the FY2025 annual result came in at $810.3 million, up 47.78% from the prior year.
• Equity Average improved to $1.1 billion in Q1 2026 per APGE's latest filing, from $745.1 million in the prior quarter.
• Across five years, Equity Average topped out at $1.1 billion in Q1 2026 and bottomed at -$55.5 million in Q2 2023.
• The 5-year median for Equity Average is $602.9 million (2025), against an average of $470.2 million.
• The widest annual swing landed in 2024, when Equity Average jumped 1540.11%; it then retreated 20.05% in 2025.
• Tracing APGE's Equity Average over 5 years: stood at -$29.7 million in 2022, then jumped by 1426.71% to $394.6 million in 2023, then soared by 83.89% to $725.6 million in 2024, then increased by 2.69% to $745.1 million in 2025, then surged by 44.92% to $1.1 billion in 2026.
• Per Business Quant, the three latest APGE Equity Average figures stand at $1.1 billion (Q1 2026), $745.1 million (Q4 2025), and $602.9 million (Q3 2025).

Peer Comparison